We have a comprehensive test assortment for the diagnosis of COVID-19. We offer two different rapid tests which mainly stand out due to their various product design and are suitable for various purposes of use. Both tests have excellent performance data. Both tests are sensitive as against different mutations. Both tests are approved as anterio-nasal tests.
Our both tests prove pathogen-specific N-proteins (Nucleocapsid -N) and thus also identify the new virus mutations. This is a mandatory criterion of the Federal Institute for Drugs and Medical Devices (BfArM) since the 15.01.2021.Furthermore both test are listed at the Federal Institute for Drugs and Medical Devices (BfArM).
Both test are evaluated by the Paul-Ehrlich Institute (PEI).